Citius Oncology, Inc. last reported quarterly results on Oct 26, 2026, for Q4 FY2026 (the quarter ended Sep 30, 2026). It usually reports 26–45 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 12, 2027.
Results for Q1 FY2027, the quarter ending around Dec 31, 2026. Expected on a Friday. Based on last year's release for the same quarter on Feb 13, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 26–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 26, 2026
26 days after quarter end
|
Q4 FY2026
ended Sep 30, 2026
|
—
|
—
|
—
|
|
Aug 14, 2026
45 days after quarter end
|
Q3 FY2026
ended Jun 30, 2026
|
1
|
-9
-66.2%
|
-0.08
+0.0%
|
|
May 15, 2026
45 days after quarter end
|
Q2 FY2026
ended Mar 31, 2026
|
2
|
-27
-244.0%
|
-0.27
-145.5%
|
|
Feb 13, 2026
44 days after quarter end
|
Q1 FY2026
ended Dec 31, 2025
|
4
|
-6
+16.9%
|
-0.06
+33.3%
|
|
Aug 12, 2025
43 days after quarter end
|
Q3 FY2025
ended Jun 30, 2025
|
—
|
-5
|
-0.08
|
|
May 14, 2025
44 days after quarter end
|
Q2 FY2025
ended Mar 31, 2025
|
—
|
-8
-62.1%
|
-0.11
-57.1%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTOR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Cranford, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1851484
- Former names
- TenX Keane Acquisition (until Aug 5, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.